At a glance
- Originator sigma-tau SpA
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 21 Sep 2006 No development reported - Preclinical for Type-2 diabetes mellitus in Italy (unspecified route)
- 20 Sep 2002 Preclinical trials in Type-2 diabetes mellitus in Italy (unspecified route)